Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | NPR3 | P17342 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1610047 | 0.84 | PDE10A (0.49) | PDE10A | |
| SCHEMBL1749359 | 0.80 | MAPK8 (0.43) | NPSR1CYP2C9NPR3CYP2C19LRRK2 | |
| SCHEMBL1749360 | 0.80 | MAPK8 (0.43) | NPSR1CYP2C9NPR3CYP2C19LRRK2 | |
| SCHEMBL1610275 | 0.79 | PDE10A (0.57) | PDE10A | |
| SCHEMBL1610199 | 0.79 | PDE10A (0.53) | PDE10A | |
| SCHEMBL1610447 | 0.79 | KDM4E (0.43) | NPSR1ADORA3ADORA1ADORA2A | |
| SCHEMBL1610242 | 0.78 | PTGER4 (0.38) | NPSR1CYP2C9LRRK2ADORA3ADORA1 | |
| SCHEMBL1609810 | 0.78 | PDE10A (0.56) | EHMT2PDE10A | |
| SCHEMBL29173624 | 0.78 | PLAU (0.41) | NPSR1CYP2C9NPR3CYP2C19LRRK2 | |
| SCHEMBL4235637 | 0.77 | LRRK2 (0.47) | NPSR1LRRK2ADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086759-A1 | CHEMICAL COMPOUNDS | SYNGENTA CROP PROTECTION, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110086759-A1 | CHEMICAL COMPOUNDS | SYNGENTA CROP PROTECTION, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110086759-A1 | CHEMICAL COMPOUNDS | SYNGENTA CROP PROTECTION, INC. (US) | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086759-A1 | CHEMICAL COMPOUNDS | DDT, PNPO, CBR3 | NPSR1 2070/4885CYP2C9 208/4885NPR3 950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.